Why the study?
Does a specific renin-inhibitory peptide reduce mean arterial pressure in sodium-depleted and renin-dependent hypertensive monkey models?
Does a specific renin-inhibitory peptide reduce mean arterial pressure in sodium-depleted and renin-dependent hypertensive monkey models?
A specific angiotensinogen analog effectively inhibits renin in vivo, reducing blood pressure in sodium-depleted and renin-dependent hypertensive monkey models.
Answers are grounded in this paper and cite their sources.
Supports BP reduction by renin-inhibitory peptide in monkey models; leaves open translation to human hypertension.
The angiotensin substrate analog Pro-His-Pro-Phe-His-Phe-Phe-Val-Tyr-Lys has no significant effect on blood pressure in sodium-replete monkeys (Macaca fascicularis) but blocks the pressor response to infused human renin. Pressor responses to angiotensin I and angiotensin II are not attenuated. In five studies in sodium-depleted monkeys, an infusion of 2 mg of the peptide per kg of body weight resulted in a reduction of mean arterial pressure (MAP) from 105 +/- 4 to 79 +/- 3 mm Hg, which is not significantly different from the response to 1 mg of the angiotensin I-converting enzyme inhibitor teprotide per kg. In uninephrectomized monkeys, inflation of a suprarenal aortic cuff caused an increase in MAP from 107 +/- 3 to 131 +/- 3 mm Hg. Infusion of 0.6 mg of the renin-inhibitory peptide per kg was followed by a return of blood pressure to 107 +/- 4 mm Hg--a depressor response similar to that observed with teprotide. This specific in vivo inhibitor of renin can now be applied to a wide variety of physiologic studies.
No takes yet. Share an insight, caveat, or question.
Burton et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: